Research programme: tyrosine kinase 2 inhibitors - Sudo Biosciences
Alternative Names: TYK2 inhibitor therapeutics - Sudo Biosciences; TYK2 pseudokinase inhibitor therapeutics - Sudo BiosciencesLatest Information Update: 17 Jul 2023
At a glance
- Originator Sudo Biosciences
- Class Eye disorder therapies; Skin disorder therapies; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Eye disorders; Skin disorders